Brief: Astellas Pharma Inc - Update On Izervay (Avacincaptad Pegol Intravitreal Solution) Supplemental New Drug Application
18/11/2024 23:01
Nov 19 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC - UPDATE ON IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL
SOLUTION) SUPPLEMENTAL NEW DRUG APPLICATION
Source text: ID:nTSwr80660
Further company coverage: 4503.T
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn